L14-8
L14-8 is a potent ferroptosis inducer. L14-8 promotes PLK1 degradation via ubiquitination, increasing TP53 phosphorylation to enhance SAT1 transcription, thereby triggering ferroptosis and cancer cell death. L14-8 can be used for the study of advanced prostate cancer[1].
Product Specifications
UNSPSC
12352005
Target
Ferroptosis; MDM-2/p53; Polo-like Kinase (PLK)
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Cancer; Endocrinology
Smiles
FC1=CC=C([C@@H](OC(C=C)=O)CC[C@@H]2[C@@H](C3=CC=C(OC(C=C)=O)C=C3)N(C4=CC=C(F)C=C4)C2=O)C=C1
Molecular Formula
C30H25F2NO5
Molecular Weight
517.52
References & Citations
[1]Zhang Y, et al. Ezetimibe Engineered L14-8 Suppresses Advanced Prostate Cancer by Activating PLK1/TP53-SAT1-Induced Ferroptosis. Adv Sci (Weinh) . 2025 Jun 19:e04192.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6419016-01 0.1 mL
GPI (Glucose-6-phosphate Isomerase, Autocrine Motility Factor, Neuroleukin, AMF, NLK, PGI, PHI, GNPI, SA36, SA-36) (AP)
Sign In for Pricing
View Details MBS6419016-02 5x 0.1 mL
GPI (Glucose-6-phosphate Isomerase, Autocrine Motility Factor, Neuroleukin, AMF, NLK, PGI, PHI, GNPI, SA36, SA-36) (AP)
Sign In for Pricing
View Details 